INO:NASDAQ

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

"I understand Inovio Pharmaceuticals Inc. is using active DNA vaccines. Inovio and OncoSec Medical are both seemingly following a similar theme, and the growing acceptance and excitement around immunotherapies in general may help them both. Inovio has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today. Thus, it has a market cap of about $590M today, versus OncoSec's $57M." read more >

Yi Chen, H.C. Wainwright & Co. (5/13/15)
"Inovio Pharmaceuticals Inc. announced yesterday that the company had initiated a Phase 1 trial to evaluate its DNA immunotherapy (INO-4212) for Ebola, which protected 100% of immunized animals from death and sickness in prior preclinical testing. . .Inovio recorded Q1/15 diluted EPS at $0.17/share, in line with our original projection."

Charles Duncan, Piper Jaffray & Co. (5/11/15)
"Inovio Pharmaceuticals Inc.'s strengthened cash and clinical trials bode well for a broadening pipeline. . .recent grants from DARPA and NIAID, potentially totaling $73M, further enhance our confidence in the company's broadly applicable DNA-based immunotherapy platform. In advance of increasing visibility of clinical programs in virally mediated cancer and infectious disease, and strengthening financial position, we reiterate our Overweight rating and our price target increases."

Jason Kolbert, Maxim Group (5/11/15)
"Inovio Pharmaceuticals Inc. reported Q1/15 revenues of $5.2M. . .the company finished Q1/15 with $81M in cash. It also completed an $87.4M ($82.1M net proceeds) public offering on May 5, 2015. . .with $163M in cash, Inovio can fund multiple programs, including the VGX-3100 Phase 3 study, through 2018."

Clinically Sound Investor, Seeking Alpha (4/24/15)
"The first of Inovio Pharmaceuticals Inc.'s four new clinical trials expected in H1/15 began dosing this week. Investors can anticipate results for at least two vaccine trials sometime this year; other possible catalysts are further funding and partnerships."

Yi Chen, H.C. Wainwright & Co. (4/22/15)
"Inovio Pharmaceuticals Inc. announced early yesterday morning that the company had initiated a Phase 1 trial to evaluate its DNA immunotherapy in chronic hepatitis B patients. . .this clinical trial is paid for by Roche Holding AG and triggers a $3M milestone payment from Roche to Inovio. . .we reiterate our Buy rating and 12-month price target of $17/share."

More Expert Comments

Experts Commenting on This Company

Yi Chen, Managing Director of Equity Research – H.C. Wainwright & Co.
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Brian Klein, Analyst – Stifel Nicolaus
Jason Kolbert, Head of Healthcare Research and Senior Biotechnology Analyst – Maxim Group
Jason Russ, Author Seeking Alpha
Ram Selvaraju, Senior Analyst – MLV & Co
Ross Silver, Co-Founder and Principal Analyst – Vista Partners
Jill Wahleithner, Fund Manager – Wasatch Funds

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Inovio Pharmaceuticals Inc. Content